Given the absence of a specific drug directly designed to interact with MYC, largely due to its non-possession of an enzymatic pocket and inaccessibility to antibodies, thiram represents an alternative strategy for addressing MYC as a target in cancer treatment, focusing on the regulation of MYC mRNA translation.52 The superior efficacy of Trmt61a siRNA compared to αPD-L1 may be attributed to its ability to inhibit the MYC pathway (Fig. S15b, c). This evidence concerns the gene MYC and cancer.